{"id":4880,"date":"2025-08-13T14:22:05","date_gmt":"2025-08-13T04:22:05","guid":{"rendered":"\/eu-uk\/?p=4880"},"modified":"2025-08-13T14:24:03","modified_gmt":"2025-08-13T04:24:03","slug":"commercialisation-of-remplir-into-us-market-continues-to-build-momentum","status":"publish","type":"post","link":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/","title":{"rendered":"Commercialisation of Remplir\u2122 into US Market Continues to Build Momentum"},"content":{"rendered":"<p>Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplir\u2122 in the US.<\/p>\n<p>Key achievements include:<\/p>\n<ul>\n<li>Ten surgeries have now taken place in the US. Experience in existing markets has demonstrated the importance of these early surgeries in the path towards more widespread adoption.<\/li>\n<li>36 applications have been lodged to hospital Value Assessment Committees (VACs) with 3 approvals already received. VAC approval is an important and necessary step in achieving widespread surgical adoption in the US hospital system.<\/li>\n<li>4,000 Remplir units have been shipped to Orthocell\u2019s US logistics provider, Uniphar, for use in US surgical procedures. All units have been manufactured at the Company\u2019s manufacturing facility in Western Australia.<\/li>\n<li>Two new employees have been hired in the US, including a regional sales director with direct experience in the nerve repair product market.<\/li>\n<\/ul>\n<p>Orthocell CEO, Paul Anderson, said:<\/p>\n<p>\u201cWe continue to make excellent progress in the US with surgeons building familiarity through early surgical procedures. We\u2019ve seen the strategic importance of these early procedures in our successful market launches of Remplir in Australia and Singapore.<\/p>\n<p>Our network of distributors remains an important avenue to market and they have been instrumental in identifying key hospitals for us to target VAC approvals. This is the next important step for us in order to achieve more widespread adoption of Remplir, which in turn will drive revenue generation for Orthocell.\u201d<\/p>\n<p><a href=\"https:\/\/bit.ly\/OCC_Remplir_US_Update\">Click to read the ASX release.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplir\u2122 in the US.<\/p>\n","protected":false},"author":2,"featured_media":4882,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-4880","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.8 - aioseo.com -->\n\t<meta name=\"description\" content=\"Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplir\u2122 in the US.\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Orthocell\"\/>\n\t<link rel=\"canonical\" href=\"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.8\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_GB\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Orthocell EU\/UK -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Commercialisation of Remplir\u2122 into US Market Continues to Build Momentum - Orthocell EU\/UK\" \/>\n\t\t<meta property=\"og:description\" content=\"Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplir\u2122 in the US.\" \/>\n\t\t<meta property=\"og:url\" content=\"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2025-08-13T04:22:05+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-08-13T04:24:03+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Commercialisation of Remplir\u2122 into US Market Continues to Build Momentum - Orthocell EU\/UK\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplir\u2122 in the US.\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2025\\\/08\\\/13\\\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\\\/#blogposting\",\"name\":\"Commercialisation of Remplir\\u2122 into US Market Continues to Build Momentum - Orthocell EU\\\/UK\",\"headline\":\"Commercialisation of Remplir\\u2122 into US Market Continues to Build Momentum\",\"author\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/author\\\/hcartres\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2025\\\/08\\\/US-Commercialisation-Update-1.png\",\"width\":2000,\"height\":1429},\"datePublished\":\"2025-08-13T14:22:05+10:00\",\"dateModified\":\"2025-08-13T14:24:03+10:00\",\"inLanguage\":\"en-GB\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2025\\\/08\\\/13\\\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2025\\\/08\\\/13\\\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\\\/#webpage\"},\"articleSection\":\"Company News\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2025\\\/08\\\/13\\\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/category\\\/company-news\\\/#listItem\",\"name\":\"Company News\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/category\\\/company-news\\\/#listItem\",\"position\":2,\"name\":\"Company News\",\"item\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/category\\\/company-news\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2025\\\/08\\\/13\\\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\\\/#listItem\",\"name\":\"Commercialisation of Remplir\\u2122 into US Market Continues to Build Momentum\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2025\\\/08\\\/13\\\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\\\/#listItem\",\"position\":3,\"name\":\"Commercialisation of Remplir\\u2122 into US Market Continues to Build Momentum\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/category\\\/company-news\\\/#listItem\",\"name\":\"Company News\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/#organization\",\"name\":\"Orthocell EU\\\/UK\",\"url\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/author\\\/hcartres\\\/#author\",\"url\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/author\\\/hcartres\\\/\",\"name\":\"Orthocell\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2025\\\/08\\\/13\\\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0aab809366bb46167bf34d1c56223f53c568b96a5870f19d01139e3e4a20c2f1?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Orthocell\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2025\\\/08\\\/13\\\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\\\/#webpage\",\"url\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2025\\\/08\\\/13\\\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\\\/\",\"name\":\"Commercialisation of Remplir\\u2122 into US Market Continues to Build Momentum - Orthocell EU\\\/UK\",\"description\":\"Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplir\\u2122 in the US.\",\"inLanguage\":\"en-GB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2025\\\/08\\\/13\\\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/author\\\/hcartres\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/author\\\/hcartres\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/wp-content\\\/uploads\\\/sites\\\/6\\\/2025\\\/08\\\/US-Commercialisation-Update-1.png\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2025\\\/08\\\/13\\\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\\\/#mainImage\",\"width\":2000,\"height\":1429},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/blog\\\/2025\\\/08\\\/13\\\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\\\/#mainImage\"},\"datePublished\":\"2025-08-13T14:22:05+10:00\",\"dateModified\":\"2025-08-13T14:24:03+10:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/#website\",\"url\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/\",\"name\":\"Orthocell EU\\\/UK\",\"inLanguage\":\"en-GB\",\"publisher\":{\"@id\":\"https:\\\/\\\/orthocell.com\\\/eu-uk\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Commercialisation of Remplir\u2122 into US Market Continues to Build Momentum - Orthocell EU\/UK","description":"Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplir\u2122 in the US.","canonical_url":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/#blogposting","name":"Commercialisation of Remplir\u2122 into US Market Continues to Build Momentum - Orthocell EU\/UK","headline":"Commercialisation of Remplir\u2122 into US Market Continues to Build Momentum","author":{"@id":"\/eu-uk\/blog\/author\/hcartres\/#author"},"publisher":{"@id":"\/eu-uk\/#organization"},"image":{"@type":"ImageObject","url":"\/eu-uk\/wp-content\/uploads\/sites\/6\/2025\/08\/US-Commercialisation-Update-1.png","width":2000,"height":1429},"datePublished":"2025-08-13T14:22:05+10:00","dateModified":"2025-08-13T14:24:03+10:00","inLanguage":"en-GB","mainEntityOfPage":{"@id":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/#webpage"},"isPartOf":{"@id":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/#webpage"},"articleSection":"Company News"},{"@type":"BreadcrumbList","@id":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/orthocell.com\/eu-uk#listItem","position":1,"name":"Home","item":"https:\/\/orthocell.com\/eu-uk","nextItem":{"@type":"ListItem","@id":"\/eu-uk\/blog\/category\/company-news\/#listItem","name":"Company News"}},{"@type":"ListItem","@id":"\/eu-uk\/blog\/category\/company-news\/#listItem","position":2,"name":"Company News","item":"\/eu-uk\/blog\/category\/company-news\/","nextItem":{"@type":"ListItem","@id":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/#listItem","name":"Commercialisation of Remplir\u2122 into US Market Continues to Build Momentum"},"previousItem":{"@type":"ListItem","@id":"https:\/\/orthocell.com\/eu-uk#listItem","name":"Home"}},{"@type":"ListItem","@id":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/#listItem","position":3,"name":"Commercialisation of Remplir\u2122 into US Market Continues to Build Momentum","previousItem":{"@type":"ListItem","@id":"\/eu-uk\/blog\/category\/company-news\/#listItem","name":"Company News"}}]},{"@type":"Organization","@id":"\/eu-uk\/#organization","name":"Orthocell EU\/UK","url":"\/eu-uk\/"},{"@type":"Person","@id":"\/eu-uk\/blog\/author\/hcartres\/#author","url":"\/eu-uk\/blog\/author\/hcartres\/","name":"Orthocell","image":{"@type":"ImageObject","@id":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/0aab809366bb46167bf34d1c56223f53c568b96a5870f19d01139e3e4a20c2f1?s=96&d=mm&r=g","width":96,"height":96,"caption":"Orthocell"}},{"@type":"WebPage","@id":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/#webpage","url":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/","name":"Commercialisation of Remplir\u2122 into US Market Continues to Build Momentum - Orthocell EU\/UK","description":"Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplir\u2122 in the US.","inLanguage":"en-GB","isPartOf":{"@id":"\/eu-uk\/#website"},"breadcrumb":{"@id":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/#breadcrumblist"},"author":{"@id":"\/eu-uk\/blog\/author\/hcartres\/#author"},"creator":{"@id":"\/eu-uk\/blog\/author\/hcartres\/#author"},"image":{"@type":"ImageObject","url":"\/eu-uk\/wp-content\/uploads\/sites\/6\/2025\/08\/US-Commercialisation-Update-1.png","@id":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/#mainImage","width":2000,"height":1429},"primaryImageOfPage":{"@id":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/#mainImage"},"datePublished":"2025-08-13T14:22:05+10:00","dateModified":"2025-08-13T14:24:03+10:00"},{"@type":"WebSite","@id":"\/eu-uk\/#website","url":"\/eu-uk\/","name":"Orthocell EU\/UK","inLanguage":"en-GB","publisher":{"@id":"\/eu-uk\/#organization"}}]},"og:locale":"en_GB","og:site_name":"Orthocell EU\/UK -","og:type":"article","og:title":"Commercialisation of Remplir\u2122 into US Market Continues to Build Momentum - Orthocell EU\/UK","og:description":"Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplir\u2122 in the US.","og:url":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/","article:published_time":"2025-08-13T04:22:05+00:00","article:modified_time":"2025-08-13T04:24:03+00:00","twitter:card":"summary_large_image","twitter:title":"Commercialisation of Remplir\u2122 into US Market Continues to Build Momentum - Orthocell EU\/UK","twitter:description":"Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplir\u2122 in the US."},"aioseo_meta_data":[],"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/orthocell.com\/eu-uk\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"\/eu-uk\/blog\/category\/company-news\/\" title=\"Company News\">Company News<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tCommercialisation of Remplir\u2122 into US Market Continues to Build Momentum\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/orthocell.com\/eu-uk"},{"label":"Company News","link":"\/eu-uk\/blog\/category\/company-news\/"},{"label":"Commercialisation of Remplir\u2122 into US Market Continues to Build Momentum","link":"\/eu-uk\/blog\/2025\/08\/13\/commercialisation-of-remplir-into-us-market-continues-to-build-momentum\/"}],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=4880"}],"version-history":[{"count":1,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4880\/revisions"}],"predecessor-version":[{"id":4881,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4880\/revisions\/4881"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/4882"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=4880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=4880"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=4880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}